BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol 2007;102:820-8. [PMID: 17222320 DOI: 10.1111/j.1572-0241.2007.01045.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 92] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Plank JR, Glover SC, Moloney BD, Hoeh NR, Sundram F, Sumner RL, Muthukumaraswamy S, Lin JC. A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder. Trials 2022;23:822. [PMID: 36175917 DOI: 10.1186/s13063-022-06738-3] [Reference Citation Analysis]
2 Plank J, Glover SC, Moloney BD, Hoeh NR, Sundram F, Sumner RL, Muthukumaraswamy S, Lin JC. A randomised, double-blind, placebo-controlled, hybrid parallel arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder.. [DOI: 10.21203/rs.3.rs-1982600/v1] [Reference Citation Analysis]
3 Pitt B, Tate AM, Gluck D, Rosenson RS, Goonewardena SN. Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19. European Heart Journal - Cardiovascular Pharmacotherapy 2022;8:402-405. [DOI: 10.1093/ehjcvp/pvac014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Paulides E, Lie MRKL, van der Woude CJ. Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn's disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study. BMJ Open 2022;12:e058358. [PMID: 35396307 DOI: 10.1136/bmjopen-2021-058358] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Meridor K, Berookhim J, Levy Y. Low dose naloxone for pruritus in systemic sclerosis: Case series and literature review. Medicine (Baltimore) 2022;101:e28653. [PMID: 35089206 DOI: 10.1097/MD.0000000000028653] [Reference Citation Analysis]
6 Huang H, Liu B, Qu N, Zhang S, Bai X, Handley M, Shan F. Research progress of opioid growth factor in immune-related diseases and cancer diseases. Int Immunopharmacol 2021;99:107713. [PMID: 34426103 DOI: 10.1016/j.intimp.2021.107713] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Qu N, Meng Y, Handley MK, Wang C, Shan F. Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy. Int Immunopharmacol 2021;96:107714. [PMID: 33989971 DOI: 10.1016/j.intimp.2021.107714] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Toledano AC. The Preventive Treatment of Migraine with Low-Dose naltrexone and acetaminophen Combination: Findings of a Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial with an Open-Label Extension for None-Responders.. [DOI: 10.1101/2021.03.23.21254186] [Reference Citation Analysis]
9 Toledano AC. The Acute Treatment of Migraine with Low-Dose Naltrexone and acetaminophen Combinations and Each Component: Findings of a Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial.. [DOI: 10.1101/2021.03.22.21254145] [Reference Citation Analysis]
10 Domnina YM, Suslov VV, Kedik SA, Volkova PO. Approaches to the Development of a Low-dose Naltrexone Preparation in the Form of a Nasal Spray (Review). Razrabotka i registraciâ lekarstvennyh sredstv 2021;10:37-47. [DOI: 10.33380/2305-2066-2021-10-1-37-47] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Kim PS, Fishman MA. Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review. Curr Pain Headache Rep 2020;24:64. [PMID: 32845365 DOI: 10.1007/s11916-020-00898-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
12 Gudin J, Kaufman AG, Datta S. Are Opioids Needed to Treat Chronic Low Back Pain? A Review of Treatment Options and Analgesics in Development. J Pain Res 2020;13:1007-22. [PMID: 32523371 DOI: 10.2147/JPR.S226483] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
13 Lajevardi V, Salarvand F, Ghiasi M, Nasimi M, Taraz M. The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled clinical trial. J Dermatolog Treat 2020;:1-5. [PMID: 32449418 DOI: 10.1080/09546634.2020.1774488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Mazahery C, Benson BL, Cruz-Lebrón A, Levine AD. Chronic Methadone Use Alters the CD8+ T Cell Phenotype In Vivo and Modulates Its Responsiveness Ex Vivo to Opioid Receptor and TCR Stimuli. J Immunol 2020;204:1188-200. [PMID: 31969385 DOI: 10.4049/jimmunol.1900862] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
15 Bobo TR, Fitzpatrick LR, Whitcomb TL, Cooper TK, Raiciulescu S, Smith JP. Role of the δ-Opioid Receptor in 2 Murine Models of Colitis. Comp Med 2020;70:25-34. [PMID: 31969211 DOI: 10.30802/AALAS-CM-19-000024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Zappaterra M, Shouse E, Levine RL. Low-Dose Naltrexone reduces symptoms in Stiff-Person Syndrome. Med Hypotheses 2020;137:109546. [PMID: 31954293 DOI: 10.1016/j.mehy.2019.109546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
17 Raknes G, Småbrekke L. Changes in the consumption of antiepileptics and psychotropic medicines after starting low dose naltrexone: A nation-wide register-based controlled before-after study. Sci Rep 2019;9:15085. [PMID: 31636347 DOI: 10.1038/s41598-019-51569-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Duque-Díaz E, Alvarez-Ojeda O, Coveñas R. Enkephalins and ACTH in the mammalian nervous system. Vitam Horm 2019;111:147-93. [PMID: 31421699 DOI: 10.1016/bs.vh.2019.05.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
19 Lee B, Elston DM. The uses of naltrexone in dermatologic conditions. Journal of the American Academy of Dermatology 2019;80:1746-52. [DOI: 10.1016/j.jaad.2018.12.031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
20 Trofimovitch D, Baumrucker SJ. Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes. Am J Hosp Palliat Care 2019;36:907-12. [PMID: 30917675 DOI: 10.1177/1049909119838974] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
21 Mcdermott MT. Low-Dose Naltrexone Treatment of Hashimoto’s Thyroiditis. Management of Patients with Pseudo-Endocrine Disorders 2019. [DOI: 10.1007/978-3-030-22720-3_24] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Zagon IS, McLaughlin PJ. Intermittent blockade of OGFr and treatment of autoimmune disorders. Exp Biol Med (Maywood) 2018;243:1323-30. [PMID: 30541348 DOI: 10.1177/1535370218817746] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
23 Skrzypacz M. Low doses of naltrexone as an analgesic used in the treatment of ZZSK ‒ case report. BÓL 2018;19:47-50. [DOI: 10.5604/01.3001.0012.8305] [Reference Citation Analysis]
24 Horowitz RI, Freeman PR. Precision Medicine: The Role of the MSIDS Model in Defining, Diagnosing, and Treating Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome and Other Chronic Illness: Part 2. Healthcare (Basel) 2018;6:E129. [PMID: 30400667 DOI: 10.3390/healthcare6040129] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
25 Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization. Med Sci (Basel) 2018;6:E82. [PMID: 30248938 DOI: 10.3390/medsci6040082] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
26 Li Z, You Y, Griffin N, Feng J, Shan F. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. International Immunopharmacology 2018;61:178-84. [DOI: 10.1016/j.intimp.2018.05.020] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
27 Miskoff JA, Chaudhri M. Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion. Cureus 2018;10:e2924. [PMID: 30197847 DOI: 10.7759/cureus.2924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
28 Raknes G, Simonsen P, Småbrekke L. The Effect of Low-Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before-and-After Prescription Database Study. J Crohns Colitis 2018;12:677-86. [PMID: 29385430 DOI: 10.1093/ecco-jcc/jjy008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
29 Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2018;4:CD010410. [PMID: 29607497 DOI: 10.1002/14651858.CD010410.pub3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
30 Lie MRKL, van der Giessen J, Fuhler GM, de Lima A, Peppelenbosch MP, van der Ent C, van der Woude CJ. Low dose Naltrexone for induction of remission in inflammatory bowel disease patients. J Transl Med 2018;16:55. [PMID: 29523156 DOI: 10.1186/s12967-018-1427-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
31 Parian AM, Mullin GE, Langhorst J, Brown AC. Inflammatory Bowel Disease. Integrative Medicine 2018. [DOI: 10.1016/b978-0-323-35868-2.00050-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Ibrahim O, Hogan SR, Vij A, Fernandez AP. Low-Dose Naltrexone Treatment of Familial Benign Pemphigus (Hailey-Hailey Disease). JAMA Dermatol 2017;153:1015-7. [PMID: 28768314 DOI: 10.1001/jamadermatol.2017.2445] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
33 Hua S, Dias TH, Pepperall DG, Yang Y. Topical Loperamide-Encapsulated Liposomal Gel Increases the Severity of Inflammation and Accelerates Disease Progression in the Adjuvant-Induced Model of Experimental Rheumatoid Arthritis. Front Pharmacol 2017;8:503. [PMID: 28824428 DOI: 10.3389/fphar.2017.00503] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
34 Stockdale DP, Titunick MB, Biegler JM, Reed JL, Hartung AM, Wiemer DF, McLaughlin PJ, Neighbors JD. Selective opioid growth factor receptor antagonists based on a stilbene isostere. Bioorg Med Chem 2017;25:4464-74. [PMID: 28693915 DOI: 10.1016/j.bmc.2017.06.035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
35 Coppes OJM, Sang CN. Indications for Opioid Antagonists. Curr Pain Headache Rep 2017;21. [DOI: 10.1007/s11916-017-0630-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
36 Poznanski P, Lesniak A, Korostynski M, Szklarczyk K, Lazarczyk M, Religa P, Bujalska-Zadrozny M, Sadowski B, Sacharczuk M. Delta-opioid receptor antagonism leads to excessive ethanol consumption in mice with enhanced activity of the endogenous opioid system. Neuropharmacology 2017;118:90-101. [PMID: 28322978 DOI: 10.1016/j.neuropharm.2017.03.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
37 Mischoulon D, Hylek L, Yeung AS, Clain AJ, Baer L, Cusin C, Ionescu DF, Alpert JE, Soskin DP, Fava M. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord 2017;208:6-14. [PMID: 27736689 DOI: 10.1016/j.jad.2016.08.029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
38 Berkson BM, Rubin DM, Berkson AJ. Reversal of Signs and Symptoms of a B-Cell Lymphoma in a Patient Using Only Low-Dose Naltrexone. Integr Cancer Ther 2007;6:293-6. [DOI: 10.1177/1534735407306358] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
39 Tawfik DI, Osman AS, Tolba HM, Khattab A, Abdel-Salam LO, Kamel MM. Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats. Neuropeptides 2016;59:39-45. [PMID: 27392602 DOI: 10.1016/j.npep.2016.06.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
40 Naltrexone. Meyler's Side Effects of Drugs 2016. [DOI: 10.1016/b978-0-444-53717-1.01129-x] [Reference Citation Analysis]
41 Literaturverzeichnis. Mitochondropathien 2016. [DOI: 10.1016/b978-3-437-31618-0.16001-8] [Reference Citation Analysis]
42 Roginsky G, Alexoff A, Ehrenpreis ED. Initial Findings of an Open-Label Trial of Low-Dose Naltrexone for Symptomatic Mesenteric Panniculitis. J Clin Gastroenterol 2015;49:794-5. [PMID: 26280708 DOI: 10.1097/MCG.0000000000000398] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
43 Skrautvol K, Nåden D. Nutrition as long-term care as experienced by persons living with inflammatory bowel disease: a qualitative study. Holist Nurs Pract. 2015;29:22-32. [PMID: 25470477 DOI: 10.1097/HNP.0000000000000064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
44 Goldsmith JR, Kelly M, Freeman KB, Duro D. Combined restitutive therapy for treatment of immunosuppressive refractory Crohn disease. J Pediatr Gastroenterol Nutr 2015;60:e31-4. [PMID: 24121152 DOI: 10.1097/MPG.0000000000000191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
45 Ghai B, Bansal D, Hota D, Shah CS. Off-label, low-dose naltrexone for refractory chronic low back pain. Pain Med 2014;15:883-4. [PMID: 24967470 DOI: 10.1111/pme.12345] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
46 Weinstock LB. Naltrexone therapy for Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2014;48:742. [PMID: 24583747 DOI: 10.1097/MCG.0000000000000093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
47 Torkildsen O, Myhr KM, Wergeland S. Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS. Neurol Neuroimmunol Neuroinflamm 2014;1:e25. [PMID: 25340078 DOI: 10.1212/NXI.0000000000000025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
48 Dodou K, Armstrong A, Kelly I, Wilkinson S, Carr K, Shattock P, Whiteley P. Ex vivo studies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6β-naltrexol, using a novel LC Q-ToF MS assay. Pharm Dev Technol 2015;20:694-701. [PMID: 24785567 DOI: 10.3109/10837450.2014.915569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
49 Segal D, Macdonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2014;:CD010410. [PMID: 24558033 DOI: 10.1002/14651858.CD010410.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
50 Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol 2014;33:451-9. [PMID: 24526250 DOI: 10.1007/s10067-014-2517-2] [Cited by in Crossref: 116] [Cited by in F6Publishing: 100] [Article Influence: 12.9] [Reference Citation Analysis]
51 Sramek J, Andry JM, Ding H, Riordan HJ, Leibowitz M, Cutler NR. The effect of naltrexone on sleep parameters in healthy male volunteers. J Clin Psychopharmacol 2014;34:167-8. [PMID: 24346745 DOI: 10.1097/JCP.0b013e3182a607ff] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
52 Taylor R Jr, Pergolizzi JV Jr, Porreca F, Raffa RB. Opioid antagonists for pain. Expert Opin Investig Drugs 2013;22:517-25. [PMID: 23484859 DOI: 10.1517/13543784.2013.778973] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
53 Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65:529-538. [PMID: 23359310 DOI: 10.1002/art.37734] [Cited by in Crossref: 112] [Cited by in F6Publishing: 117] [Article Influence: 11.2] [Reference Citation Analysis]
54 Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study. J Clin Gastroenterol 2013;47:339-45. [PMID: 23188075 DOI: 10.1097/MCG.0b013e3182702f2b] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
55 Segal D, Macdonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2013. [DOI: 10.1002/14651858.cd010410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
56 Sternini C, Duraffourd C, Anselmi L. Opioids. Handbook of Biologically Active Peptides 2013. [DOI: 10.1016/b978-0-12-385095-9.00174-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 C. Ferri's Clinical Advisor 2013 2013. [DOI: 10.1016/b978-0-323-08373-7.00012-1] [Reference Citation Analysis]
58 Rogosnitzky M, Finegold MJ, Mclaughlin PJ, Zagon IS. Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment. Invest New Drugs 2013;31:1066-70. [DOI: 10.1007/s10637-012-9918-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
59 Du C, Xie X. G protein-coupled receptors as therapeutic targets for multiple sclerosis. Cell Res 2012;22:1108-28. [PMID: 22664908 DOI: 10.1038/cr.2012.87] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
60 Fucito LM, Park A, Gulliver SB, Mattson ME, Gueorguieva RV, O'Malley SS. Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. Biol Psychiatry 2012;72:832-8. [PMID: 22541040 DOI: 10.1016/j.biopsych.2012.03.023] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
61 McLaughlin PJ, Keiper CL, Verderame MF, Zagon IS. Targeted overexpression of OGFr in epithelium of transgenic mice suppresses cell proliferation and impairs full-thickness wound closure. Am J Physiol Regul Integr Comp Physiol 2012;302:R1084-90. [PMID: 22338080 DOI: 10.1152/ajpregu.00670.2011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
62 Fanning J, Hossler CA, Kesterson JP, Donahue RN, Mclaughlin PJ, Zagon IS. Expression of the opioid growth factor–opioid growth factor receptor axis in human ovarian cancer. Gynecologic Oncology 2012;124:319-24. [DOI: 10.1016/j.ygyno.2011.10.024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
63 Zagon IS, McLaughlin PJ. Targeting opioid signaling in Crohn's disease: new therapeutic pathways. Expert Rev Gastroenterol Hepatol 2011;5:555-8. [PMID: 21910569 DOI: 10.1586/egh.11.62] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
64 Galland L. Inflammatory Bowel Disease. Integrative Medicine 2012. [DOI: 10.1016/b978-1-4377-1793-8.00102-3] [Reference Citation Analysis]
65 Owczarek D, Cibor D, Mach T, Cieśla A, Pierzchała-Koziec K, Sałapa K, Kuśnierz-Cabała B. Met-enkephalins in patients with inflammatory bowel diseases. Adv Med Sci 2011;56:158-64. [PMID: 22112433 DOI: 10.2478/v10039-011-0051-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
66 Frech T, Novak K, Revelo MP, Murtaugh M, Markewitz B, Hatton N, Scholand MB, Frech E, Markewitz D, Sawitzke AD. Low-dose naltrexone for pruritus in systemic sclerosis. Int J Rheumatol 2011;2011:804296. [PMID: 21918649 DOI: 10.1155/2011/804296] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
67 Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood) 2011;236:1036-50. [PMID: 21807817 DOI: 10.1258/ebm.2011.011121] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
68 Donahue RN, Mclaughlin PJ, Zagon IS. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood) 2011;236:883-95. [DOI: 10.1258/ebm.2011.011096] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
69 Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci 2011;56:2088-97. [PMID: 21380937 DOI: 10.1007/s10620-011-1653-7] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 6.5] [Reference Citation Analysis]
70 Goldsmith JR, Uronis JM, Jobin C. Mu opioid signaling protects against acute murine intestinal injury in a manner involving Stat3 signaling. Am J Pathol 2011;179:673-83. [PMID: 21801866 DOI: 10.1016/j.ajpath.2011.04.032] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
71 Mclaughlin PJ, Stucki JK, Zagon IS. Modulation of the opioid growth factor ([Met5]-enkephalin)-opioid growth factor receptor axis: Novel therapies for squamous cell carcinoma of the head and neck. Head Neck 2012;34:513-9. [DOI: 10.1002/hed.21759] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
72 Zagon IS, Donahue RN, Bonneau RH, Mclaughlin PJ. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met5]-enkephalin)–opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Immunobiology 2011;216:579-90. [DOI: 10.1016/j.imbio.2010.09.014] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 3.7] [Reference Citation Analysis]
73 Donahue RN, McLaughlin PJ, Zagon IS. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol 2011;122:382-8. [PMID: 21531450 DOI: 10.1016/j.ygyno.2011.04.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
74 Rahn KA, Mclaughlin PJ, Zagon IS. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis. Brain Research 2011;1381:243-53. [DOI: 10.1016/j.brainres.2011.01.036] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
75 Zagon IS, Donahue RN, Bonneau RH, Mclaughlin PJ. B lymphocyte proliferation is suppressed by the opioid growth factor–opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Immunobiology 2011;216:173-83. [DOI: 10.1016/j.imbio.2010.06.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
76 The ALSUntangled Group. ALSUntangled No. 8: Low dose naltrexone for ALS. Amyotrophic Lateral Sclerosis 2010;12:76-8. [DOI: 10.3109/17482968.2010.544386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
77 Genuis SJ. Sensitivity-related illness: The escalating pandemic of allergy, food intolerance and chemical sensitivity. Science of The Total Environment 2010;408:6047-61. [DOI: 10.1016/j.scitotenv.2010.08.047] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 4.5] [Reference Citation Analysis]
78 Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol 2010;68:145-50. [PMID: 20695007 DOI: 10.1002/ana.22006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 37] [Article Influence: 1.0] [Reference Citation Analysis]
79 Shannon A, Alkhouri N, Mayacy S, Kaplan B, Mahajan L. Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient. Inflamm Bowel Dis 2010;16:1457. [PMID: 20014017 DOI: 10.1002/ibd.21185] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
80 Schirbel A, Reichert A, Roll S, Baumgart DC, Büning C, Wittig B, Wiedenmann B, Dignass A, Sturm A. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol 2010; 16(25): 3168-3177 [PMID: 20593502 DOI: 10.3748/wjg.v16.i25.3168] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 97] [Article Influence: 7.5] [Reference Citation Analysis]
81 Arendt-nielsen L, Drewes AM. Opioid Antagonists and Their Role in Inflammation, Pain, and Gut Functioning. Journal of Pain & Palliative Care Pharmacotherapy 2010;24:66-69. [DOI: 10.3109/15360280903583172] [Reference Citation Analysis]
82 Ghodse A, Galea S. Opioid analgesics and narcotic antagonists. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Elsevier; 2010. pp. 183-224. [DOI: 10.1016/s0378-6080(10)32008-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
83 Zagon IS, Rahn KA, Turel AP, Mclaughlin PJ. Endogenous Opioids Regulate Expression of Experimental Autoimmune Encephalomyelitis: A New Paradigm for the Treatment of Multiple Sclerosis. Exp Biol Med (Maywood) 2009;234:1383-92. [DOI: 10.3181/0906-rm-189] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
84 Uhelski ML, Fuchs PN. Naltrexone fails to increase pain affect in response to inflammatory pain in a novel escape/avoidance paradigm. Physiol Behav 2009;98:263-7. [PMID: 19505486 DOI: 10.1016/j.physbeh.2009.05.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
85 Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 2009;10:663-72. [PMID: 19453963 DOI: 10.1111/j.1526-4637.2009.00613.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 144] [Article Influence: 9.6] [Reference Citation Analysis]
86 Reece AS. Improved parameters of metabolic glycaemic and immune function and arterial stiffness with naltrexone implant therapy. BMJ Case Rep 2009;2009:bcr0820080799. [PMID: 21687046 DOI: 10.1136/bcr.08.2008.0799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
87 Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Medical Hypotheses 2009;72:333-7. [DOI: 10.1016/j.mehy.2008.06.048] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 4.5] [Reference Citation Analysis]
88 Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler 2008;14:1076-83. [PMID: 18728058 DOI: 10.1177/1352458508095828] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 4.1] [Reference Citation Analysis]
89 Bodnar RJ. Endogenous opiates and behavior: 2007. Peptides 2008;29:2292-375. [DOI: 10.1016/j.peptides.2008.09.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
90 Matters GL, Harms JF, Mcgovern C, Fitzpatrick L, Parikh A, Nilo N, Smith JP. The Opioid Antagonist Naltrexone Improves Murine Inflammatory Bowel Disease. Journal of Immunotoxicology 2008;5:179-87. [DOI: 10.1080/15476910802131469] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
91 Lichtenstein G. Low-Dose Naltrexone Therapy Improves Active Crohn's Disease. Yearbook of Gastroenterology 2008;2008:136-137. [DOI: 10.1016/s0739-5930(08)79050-0] [Reference Citation Analysis]